Oral β-Lactam Pairs for the Treatment of Mycobacterium avium Complex Pulmonary Disease.

ABSTRACT: Cure rates for pulmonary disease caused by the Mycobacterium avium complex (MAC) are poor. While β-lactam are front line antibiotics against Mycobacterium abscessus pulmonary disease, they have not been used or recommended to treat MAC lung infections. Through a comprehensive screen of oral β-lactams, we have discovered that selected pairs combining either a penem/carbapenem or penicillin with a cephalosporin are strongly bactericidal at clinically achieved concentrations. These dual β-lactam combinations include tebipenem and sulopenem, both in phase 3, and Food and Drug Administration-approved amoxicillin and cefuroxime. They could therefore immediately enter clinical trials or clinical practice.

SUBMITTER: Negatu DA 

PROVIDER: S-EPMC11326814 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature